KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Cash from Financing Activities (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Cash from Financing Activities for 16 consecutive years, with $27.1 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 6.9% to $27.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $53.1 million through Dec 2025, up 3.06% year-over-year, with the annual reading at $53.1 million for FY2025, 3.06% up from the prior year.
  • Cash from Financing Activities hit $27.1 million in Q4 2025 for Inovio Pharmaceuticals, up from $24.9 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $160.9 million in Q1 2021 to a low of -$11.4 million in Q1 2024.
  • Historically, Cash from Financing Activities has averaged $20.1 million across 5 years, with a median of $3.6 million in 2021.
  • Biggest five-year swings in Cash from Financing Activities: crashed 2575.77% in 2024 and later skyrocketed 3672.4% in 2025.
  • Year by year, Cash from Financing Activities stood at $47.6 million in 2021, then tumbled by 85.99% to $6.7 million in 2022, then crashed by 72.43% to $1.8 million in 2023, then soared by 1485.47% to $29.1 million in 2024, then decreased by 6.9% to $27.1 million in 2025.
  • Business Quant data shows Cash from Financing Activities for INO at $27.1 million in Q4 2025, $24.9 million in Q3 2025, and -$34777.0 in Q2 2025.